OPKO Health, Inc.
Clinical trials sponsored by OPKO Health, Inc., explained in plain language.
Healthcare company focused on diagnostics and pharmaceuticals.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
-
New MASH drug OPK-88006 enters early human testing
Disease control Recruiting nowThis early-stage study tests a new drug called OPK-88006 in 30 people, first in healthy volunteers and then in those with MASH (a serious liver condition). The goal is to check safety, how the drug moves through the body, and early signs of liver improvement. Results will help de…
Phase 1/2 • Sponsor: OPKO Health, Inc. • Aim: Disease control
Last updated Aug 29, 2026 00:00 UTC
-
New hope for kids with kidney disease: experimental vitamin d pill enters trial
Disease control Recruiting nowThis study tests an extended-release vitamin D capsule (CTAP101) in 40 children aged 8 to 17 with stage 3 or 4 chronic kidney disease, secondary hyperparathyroidism, and low vitamin D. Participants take one capsule daily at bedtime for 8 weeks. The goal is to see how the body pro…
Phase 2 • Sponsor: OPKO Health, Inc. • Aim: Disease control
Last updated Aug 22, 2026 00:00 UTC